Brodalumab for Immune-Related Side Effects
Phase 1
11
about 1.7 years
18+
1 site in NY
What this study is about
This trial is testing the safety and effectiveness of using brodalumab to manage immune-related side effects in people with cancer who are receiving immunotherapy. Brodalumab, which is used to treat autoimmune diseases, may help control these side effects by targeting similar immune system activation.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive CT scan
- 2.Take Brodalumab
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
brodalumab
Primary: Number of Adverse Events, Percentage of primary Immune-Related Adverse Event (irAE) severity decreased
Secondary: Mean Time to Complete Resolution of irAE Symptoms, Overall Survival (OS), Progression-free survival (PFS)
imaging
Oncology